ORLANDO – Duloxetine for the treatment of late-life depression missed its primary end point in a recent large randomized trial, but it did result in consistently significant clinical improvement,...

Field of Interest: Geriatrics

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.